ABSENCE OF QTC PROLONGATION WITH BETRIXABAN: A RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND POSITIVE-CONTROLLED THOROUGH ECG STUDY

ABSENCE OF QTC PROLONGATION WITH BETRIXABAN: A RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND POSITIVE-CONTROLLED THOROUGH ECG STUDY

To evaluate the effects of betrixaban on individual heart rate-corrected QT duration (QTcl), 96 healthy adults were randomly assigned to single-dose betrixaban 80 mg and 140 mg (therapeutic and supratherapeutic doses, respectively), placebo, and moxifloxacin 400 mg (positive control) in a 4-period c...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American College of Cardiology Vol. 61; no. 10; p. E271
Main Authors: Sinha, Uma, Morganroth, Joel, Gretler, Daniel D, Hollenbach, Stanley J, Lambing, Joseph L
Format: Journal Article
Language:English
Published: New York Elsevier Inc 12-03-2013
Elsevier Limited
Subjects:
Cardiology
Cardiovascular
Confidence intervals
Drug therapy
Internal Medicine
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To evaluate the effects of betrixaban on individual heart rate-corrected QT duration (QTcl), 96 healthy adults were randomly assigned to single-dose betrixaban 80 mg and 140 mg (therapeutic and supratherapeutic doses, respectively), placebo, and moxifloxacin 400 mg (positive control) in a 4-period crossover study.
ISSN:0735-1097
1558-3597
DOI:10.1016/S0735-1097(13)60271-5